Paris-based pharmaceutical giant Sanofi (NASDAQ:SNY) has received approval from the U.S. Food and Drug Administration (FDA) for an expanded use of its drug Sarclisa, in combination with other treatments, for newly diagnosed multiple myeloma patients.
Previously, Sarclisa was only approved for use after standard treatments had failed.
The FDA’s decision follows a study demonstrating that a specific treatment regimen including Sarclisa reduced the risk of disease progression or death by 40% compared to treatments without the drug.
In recognition of its potential, Sarclisa was granted FDA priority review status in May.
This approval marks a significant step forward in Sanofi’s commitment to oncology, despite challenges such as the failure of a key breast cancer drug candidate in 2022.
The company remains a leader in anti-inflammatory drugs and continues to prioritize the development of innovative cancer therapies.